About Niagen Bioscience, Inc.
Ticker
info
NAGE
Trading on
info
NASDAQ
ISIN
info
US1710774076
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Robert N. Fried
Headquarters
info
10900 Wilshire Blvd, Los Angeles, CA, United States, 90024
Employees
info
117
Website
info
niagenbioscience.com
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Metrics
BasicAdvanced
Market cap
info
$404M
P/E ratio
info
21.08
EPS
info
$0.24
Dividend Yield
info
0.00%
Beta
info
2.23
Forward P/E ratio
info
18.18
EBIDTA
info
$15.1M
Ex dividend date
info
-
Price & volume
Market cap
info
$404M
Average daily volume
info
1.5M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
21.08
Forward P/E
info
18.18
PEG ratio
info
-
Trailing P/E
info
21.08
Price to sales
info
3.12
Price to book
info
5.75
Earnings
EPS
info
$0.24
EPS estimate (current quarter)
info
$0.02
EPS estimate (next quarter)
info
$0.06
EBITDA
info
$15.1M
Revenues (TTM)
info
$129M
Revenues per share (TTM)
info
$1.64
Technicals
Beta
info
2.23
52-week High
info
$14.69
52-week Low
info
$4.73
50-day moving average
info
$5.78
200-day moving average
info
$8.46
Short ratio
info
7.82
Short %
info
12.31%
Management effectiveness
ROE (TTM)
info
28.35%
ROA (TTM)
info
10.23%
Profit margin
info
13.43%
Gross profit margin
info
$83.2M
Operating margin
info
6.22%
Growth
Quarterly earnings growth (YoY)
info
-41.60%
Quarterly revenue growth (YoY)
info
16.20%
Share stats
Outstanding Shares
info
79.8M
Float
info
52.9M
Insiders %
info
33.89%
Institutions %
info
41.68%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 4 analysts.

Average price target

info
$13.60
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.06
$0.02
200.00%
Q1 • 25Beat
$0.04
$0.02
100.00%
Q2 • 25Beat
$0.05
$0.02
150.00%
Q3 • 25Beat
$0.03
$0.02
25.45%
Q4 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$34M
$4.6M
13.47%
Q3 • 25
$33.8M
$4.1M
12.21%
Q4 • 25
-0.43%
-9.74%
-9.35%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$98.1M
$27.5M
27.98%
Q3 • 25
$106M
$29.9M
28.07%
Q4 • 25
8.42%
8.78%
0.32%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$3.7M
$-0M
$0.1M
$3.7M
Q3 • 25
$0.6M
-
$-0M
$0.5M
Q4 • 25
-83.10%
-
-116.89%
-85.74%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Niagen Bioscience, Inc. share?
Collapse

Niagen Bioscience, Inc. shares are currently traded for undefined per share.

How many shares does Niagen Bioscience, Inc. have?
Collapse

Niagen Bioscience, Inc. currently has 79.8M shares.

Does Niagen Bioscience, Inc. pay dividends?
Collapse

No, Niagen Bioscience, Inc. doesn't pay dividends.

What is Niagen Bioscience, Inc. 52 week high?
Collapse

Niagen Bioscience, Inc. 52 week high is $14.69.

What is Niagen Bioscience, Inc. 52 week low?
Collapse

Niagen Bioscience, Inc. 52 week low is $4.73.

What is the 200-day moving average of Niagen Bioscience, Inc.?
Collapse

Niagen Bioscience, Inc. 200-day moving average is $8.46.

Who is Niagen Bioscience, Inc. CEO?
Collapse

The CEO of Niagen Bioscience, Inc. is Robert N. Fried.

How many employees Niagen Bioscience, Inc. has?
Collapse

Niagen Bioscience, Inc. has 117 employees.

What is the market cap of Niagen Bioscience, Inc.?
Collapse

The market cap of Niagen Bioscience, Inc. is $404M.

What is the P/E of Niagen Bioscience, Inc.?
Collapse

The current P/E of Niagen Bioscience, Inc. is 21.08.

What is the EPS of Niagen Bioscience, Inc.?
Collapse

The EPS of Niagen Bioscience, Inc. is $0.24.

What is the PEG Ratio of Niagen Bioscience, Inc.?
Collapse

The PEG Ratio of Niagen Bioscience, Inc. is null.

What do analysts say about Niagen Bioscience, Inc.?
Collapse

According to the analysts Niagen Bioscience, Inc. is considered a buy.